Should I buy or sell Hookipa Pharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOOK shares. View HOOK analyst ratings or view top-rated stocks .

What is Hookipa Pharma's stock price target for 2024?

3 brokers have issued 12 month target prices for Hookipa Pharma's shares. Their HOOK share price targets range from $4.00 to $6.50. On average, they predict the company's stock price to reach $5.17 in the next year. This suggests a possible upside of 593.5% from the stock's current price. View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts .

How have HOOK shares performed in 2024?

Hookipa Pharma's stock was trading at $0.81 at the beginning of 2024. Since then, HOOK shares have decreased by 8.0% and is now trading at $0.7450. View the best growth stocks for 2024 here .

Are investors shorting Hookipa Pharma?

Hookipa Pharma saw a decrease in short interest in March. As of March 31st, there was short interest totaling 315,900 shares, a decrease of 5.2% from the March 15th total of 333,400 shares. Based on an average daily trading volume, of 562,100 shares, the short-interest ratio is currently 0.6 days. Approximately 0.5% of the company's stock are sold short. View Hookipa Pharma's Short Interest .

When is Hookipa Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HOOK earnings forecast .

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) issued its quarterly earnings results on Friday, March, 22nd. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $7.41 million for the quarter, compared to the consensus estimate of $3.60 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 72.30% and a negative net margin of 405.28%.

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX) , Kaleido Biosciences (KLDO) , Editas Medicine (EDIT) , Gossamer Bio (GOSS) , Atreca (BCEL) , LogicBio Therapeutics (LOGC) , Alector (ALEC) , Precision BioSciences (DTIL) , Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX) .

When did Hookipa Pharma IPO?

Hookipa Pharma (HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:HOOK

Hookipa Pharma (HOOK) Stock Price, News & Analysis

→ The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad)

Free HOOK Stock Alerts

$0.74

-0.02 (-2.75%)

(As of 01:33 PM ET)

Compare

Today's Range: $0.73
▼
$0.80
50-Day Range: $0.64
▼
$0.85
52-Week Range: $0.41
▼
$2.05

Volume: 278,804 shs
Average Volume: 564,556 shs
Market Capitalization: $73.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.17

Get Hookipa Pharma alerts:

Hookipa Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 593.5% Upside
$5.17 Price Target
Short Interest: Healthy
0.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.56
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.51) to ($0.47) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

232nd out of 918 stocks

Pharmaceutical Preparations Industry

93rd out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
Hookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Hookipa Pharma has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.45% of the float of Hookipa Pharma has been sold short.
Short Interest Ratio / Days to Cover
Hookipa Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Hookipa Pharma has recently decreased by 5.25%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Hookipa Pharma does not currently pay a dividend.
Dividend Growth
Hookipa Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HOOK.

4.2

News and Social Media Coverage

News Sentiment
Hookipa Pharma has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Hookipa Pharma this week, compared to 1 article on an average week.
Search Interest
19 people have searched for HOOK on MarketBeat in the last 30 days. This is an increase of 138% compared to the previous 30 days.
MarketBeat Follows
8 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hookipa Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.82% of the stock of Hookipa Pharma is held by insiders.
Percentage Held by Institutions
63.88% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Hookipa Pharma are expected to grow in the coming year, from ($0.51) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Hookipa Pharma is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hookipa Pharma is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Hookipa Pharma has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Hookipa Pharma Stock (NASDAQ:HOOK)

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

HOOK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HOOK Stock News Headlines

April 17, 2024 | finanznachrichten.de

HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

April 16, 2024 | finance.yahoo.com

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

April 19, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

April 16, 2024 | americanbankingnews.com

Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Down 5.2% in March

April 10, 2024 | globenewswire.com

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

March 27, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Hookipa Pharma Based on Promising HB-200 Trial Results and Strategic Trial Design

March 24, 2024 | finanznachrichten.de

HOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

March 24, 2024 | finance.yahoo.com

Time To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Outlook

April 19, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

March 23, 2024 | benzinga.com

HOOKIPA Pharma Stock (NASDAQ:HOOK), Earnings Estimates, EPS, and Revenue

March 23, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease Pipelines

March 22, 2024 | msn.com

HOOKIPA Pharma GAAP EPS of -$0.22 misses by $0.02, revenue of $7.41M beats by $2.85M

March 22, 2024 | globenewswire.com

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

March 6, 2024 | globenewswire.com

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

February 28, 2024 | morningstar.com

HOOKIPA Pharma Inc HOOK

February 22, 2024 | benzinga.com

HOOKIPA Pharma Stock (NASDAQ:HOOK) Dividends: History, Yield and Dates

February 2, 2024 | finance.yahoo.com

All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy

February 1, 2024 | markets.businessinsider.com

Maintaining Buy Rating on Hookipa Pharma Amid Strategic Repositioning and Pipeline Promise

January 31, 2024 | uk.investing.com

Hookipa Pharma Inc (HOOK)

January 29, 2024 | markets.businessinsider.com

Strategic Focus on Promising HPV+ Cancer Candidate Underpins Buy Rating for Hookipa Pharma

January 29, 2024 | markets.businessinsider.com

HOOKIPA Pharma To Cut Jobs Following Collaboration Termination By Roche

January 29, 2024 | msn.com

Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal

January 29, 2024 | marketwatch.com

HOOKIPA Pharma Shares Fall Premarket as Roche Ends Collaboration

January 16, 2024 | finanznachrichten.de

HOOKIPA Pharma Inc.: HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

January 16, 2024 | finance.yahoo.com

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

January 16, 2024 | finance.yahoo.com

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

December 22, 2023 | finanznachrichten.de

HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

See More Headlines

Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HOOK
CUSIP: N/A
CIK: 1760542
Web: www.hookipapharma.com
Phone: 431-890-6360
Fax: 43-1890-636-0399
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.17
High Stock Price Target: $6.50
Low Stock Price Target: $4.00
Potential Upside/Downside: +575.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-81,580,000.00
Net Margins: -405.28%
Pretax Margin: -403.46%
Return on Equity: -72.30%
Return on Assets: -40.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.50
Quick Ratio: 3.50

Sales & Book Value

Annual Sales: $20.13 million
Price / Sales: 3.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.91 per share
Price / Book: 0.84

Miscellaneous

Outstanding Shares: 98,950,000
Free Float: 93,191,000
Market Cap: $75.69 million
Optionable: Optionable
Beta: 1.02

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Joern Aldag (Age 60)
Pres, CEO & Director
Mr. Daniel Pinschewer (Age 44)
Founder & Chief Scientific Officer
Dr. Reinhard Kandera (Age 50)
CFO & Director
Mr. Anders Lilja Ph.D. (Age 46)
Sr. VP of Technical Devel.
Mrs. Nina Waibel
Communications & Investor Relations Mang.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HOOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOOK shares.
View HOOK analyst ratings or view top-rated stocks.
What is Hookipa Pharma's stock price target for 2024?: 3 brokers have issued 12 month target prices for Hookipa Pharma's shares. Their HOOK share price targets range from $4.00 to $6.50. On average, they predict the company's stock price to reach $5.17 in the next year. This suggests a possible upside of 593.5% from the stock's current price.
View analysts price targets for HOOK or view top-rated stocks among Wall Street analysts.
How have HOOK shares performed in 2024?: Hookipa Pharma's stock was trading at $0.81 at the beginning of 2024. Since then, HOOK shares have decreased by 8.0% and is now trading at $0.7450.
View the best growth stocks for 2024 here.
Are investors shorting Hookipa Pharma?: Hookipa Pharma saw a decrease in short interest in March. As of March 31st, there was short interest totaling 315,900 shares, a decrease of 5.2% from the March 15th total of 333,400 shares. Based on an average daily trading volume, of 562,100 shares, the short-interest ratio is currently 0.6 days. Approximately 0.5% of the company's stock are sold short.
View Hookipa Pharma's Short Interest.
When is Hookipa Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HOOK earnings forecast.

How were Hookipa Pharma's earnings last quarter?: Hookipa Pharma Inc (NASDAQ:HOOK) issued its quarterly earnings results on Friday, March, 22nd. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $7.41 million for the quarter, compared to the consensus estimate of $3.60 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 72.30% and a negative net margin of 405.28%.
What other stocks do shareholders of Hookipa Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC), Alector (ALEC), Precision BioSciences (DTIL), Akero Therapeutics (AKRO) and Dynavax Technologies (DVAX).
When did Hookipa Pharma IPO?: Hookipa Pharma (HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.
How do I buy shares of Hookipa Pharma?: Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HOOK) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial